Comparison of patient reported quality of life and impact of treatment side effects experienced with a taxane-containing regimen and standard anthracycline based chemotherapy for early breast cancer: 6year results from the UK TACT trial (CRUK/01/001)-Reference-Cited by-同舟云学术

Comparison of patient reported quality of life and impact of treatment side effects experienced with a taxane-containing regimen and standard anthracycline based chemotherapy for early breast cancer: 6year results from the UK TACT trial (CRUK/01/001)

Published:2014-09 Issue:14 Volume:50 Page:2375-2389
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Hall E.,Cameron D.,Waters R.,Barrett-Lee P.,Ellis P.,Russell S.,Bliss J.M.,Hopwood P.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference40 articles.

1. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials;Peto;Lancet,2012

2. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open label, phase 111, randomised controlled trial;Ellis;Lancet,2009

3. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02–98 randomized trial;Francis;J Natl Cancer Inst,2008

4. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7year follow-up of US Oncology Research Trial 9735;Jones;J Clin Oncol,2009

5. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B28;Mamounas;J Clin Oncol,2005

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pooled analysis of NeoCARH and NeoCART trials: patient-reported outcomes in patients with early-stage breast cancer receiving platinum-based or anthracycline-based neoadjuvant chemotherapy;Supportive Care in Cancer;2024-06

2. Adverse Event Reporting in Cancer Clinical Trials: Incorporating Patient-Reported Methods. A Systematic Scoping Review;The Patient - Patient-Centered Outcomes Research;2024-04-08

3. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial;The Lancet Oncology;2023-12

4. Adverse events connected to breast cancer treatment and their associated decrease in quality of life scores;2022-11-29

5. The nuclear receptor TLX (NR2E1) inhibits growth and progression of triple- negative breast cancer;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2022-11